Abstracts tagged "Biologicals"

Abstract Number: 0646 • ACR Convergence 2024
Chart Audit of over 1,000 SLE Patients Reveals Biologic Treatment Choice Driven by Disease Manifestations
Maxine Yarnall¹, Ryan Rex² and Sawyer May¹, ¹Spherix Global Insights, Exton, PA, ²Spherix Global Insights, Chester Springs, PA
Background/Purpose: To better understand how US rheumatologists utilize biologics in the management of SLE, especially among those with cutaneous manifestations. No medication is currently FDA-approved…
Abstract Number: 0875 • ACR Convergence 2024
Targeted IL-15 Muteins Provide Selective Expansion of KIR+ CD8 Regulatory T Cells, with the Potential to Ameliorate Disease in Autoimmune Patients with Deficient CD8 Treg Populations
Daniel Patton, Alex Chen, Justin Bowser, Kaelen Encarnacion, Jennifer Gardell, Emily Gilbertson, Susan Julien, Meghan Maurer, Brent Meengs, Nadine Morgan, Allison O'Rourke, Cong Tan, Jon Therriault, Kristine Swiderek and Courtney Crane, Mozart Therapeutics, Seattle, WA
Background/Purpose: CD8 Treg, characterized in human peripheral blood mononuclear cells (PBMC) by expression of inhibitory killer immunoglobulin receptors (KIRs), regulate immune balance by eliminating self-reactive…
Abstract Number: 1232 • ACR Convergence 2024
Patient Reported Impact of Psoriatic Arthritis and Desired Treatment Outcomes
Elizabeth Luce¹, Beth schneider² and Dianna cronin², ¹MyHealthTeam, San Francisco, CA, ²MyHealthTeams, San Francisco, CA
Background/Purpose: People living with psoriatic arthritis often struggle with the physical and mental health toll. Understanding the holistic impact of psoriatic arthritis is crucial to…
Abstract Number: 1468 • ACR Convergence 2024
Efficacy of bDMARDs in Early versus Established Disease in Axial Spondyloarthritis: A Meta-Analysis of Randomized Trials
Diego Benavent¹, Victoria Navarro Compán², Dafne Capelusnik³ and Sofia Ramiro⁴, ¹Rheumatology Department, Hospital Universitari de Bellvitge, Barcelona, Spain, CAMBRILS, Spain, ²La Paz University Hospital, Hospital La Paz Institute for Health Research (IdiPAZ), Madrid, Spain, ³Tel Aviv Sourasky Medical Center, Ramat Gan, Israel, ⁴Leiden University Medical Center, Bunde, Netherlands
Background/Purpose: The ASAS consensus definition of ‘early axial spondyloarthritis (axSpA)’ (axial symptoms ≤ 2 years) was expert-based given the scarcity of evidence1. We conducted a…
Abstract Number: 1601 • ACR Convergence 2024
Changing Spectrum of Systemic Therapies for Eosinophilic Granulomatosis with Polyangiitis from 2006-2023
Lynn Fussner¹, Christian Pagnoux², David Cuthbertson³, Thomas Corbridge⁴, Nader Khalidi⁵, Curry Koening⁶, Carol Langford⁷, Carol McAlear⁸, Paul Monach⁹, Larry Moreland¹⁰, Rennie Rhee⁸, Philip Seo¹¹, Anat Shavit¹², Jared Silver¹³, Ulrich Specks¹⁴, Kenneth Warrington¹⁴, Michael Wechsler¹⁵ and Peter Merkel⁸, and for the Vasculitis Clinical Research Consortium, ¹The Ohio State University, Columbus, OH, ²Mount Sinai Hospital, Toronto, ON, Canada, ³University of South Florida, Tampa, FL, ⁴US Value Evidence and Outcomes, GSK, Durham, NC, ⁵McMaster University, Hamilton, ON, Canada, ⁶University of Texas Dell Medical School, Austin, TX, ⁷Cleveland Clinic, Moreland Hills, OH, ⁸University of Pennsylvania, Philadelphia, PA, ⁹VA Boston Healthcare System, Boston, MA, ¹⁰University of Colorado, Denver, CO, ¹¹Johns Hopkins University, Baltimore, MD, ¹²BioPharmaceuticals Medical, AstraZeneca, Cambridge, United Kingdom, ¹³US Medical Affairs - Respiratory, GSK, Durham, ¹⁴Mayo Clinic, Rochester, MN, ¹⁵National Jewish Health, Denver, CO
Background/Purpose: The emergence of biologic therapies targeting eosinophils via the IL-5 pathway provided new options for treatment in eosinophilic granulomatosis with polyangiitis (EGPA). There has…
Abstract Number: 2032 • ACR Convergence 2024
A Systematic Review of Treatment Strategies in VEXAS Syndrome
Aviraag Vijaya Prakash¹, Jose Garcia², Anurag Goel³, Vinit Gilvaz⁴ and Raveena Midha⁵, ¹Saint Vincent Hospital, Department of Internal Medicine, Worcester, MA, ²Brown University, East Greenwich, RI, ³The Warren Alpert Medical School of Brown University, Providence, RI, ⁴The Warren Alpert Medical School of Brown University, East Providence, RI, ⁵Kent Hospital/Brown University, Warwick, RI
Background/Purpose: VEXAS (Vacuoles, E1 enzyme, X-linked, Autoinflammatory, Somatic) syndrome, first described in 2020, is an autoinflammatory condition characterized by somatic mutations in the UBA1 gene.…
Abstract Number: 2344 • ACR Convergence 2024
Secukinumab Retention and Effectiveness in Patients with Psoriatic Arthritis and Radiographic Axial Spondyloarthritis: 5-year Final Results of a Prospective Real-world Study
Uta Kiltz¹, Petros Sfikakis², Andreas Bounas³, Nicola Gullick⁴, Eric LESPESSAILLES⁵, Jan Brandt Jürgens⁶, Rasho Rashkov⁷, Barbara Schulz⁸, Weibin Bao⁹, Piotr Jagiello¹⁰ and Karl Gaffney¹¹, ¹Rheumazentrum Ruhrgebiet Herne, Ruhr-University, D-44649 Herne, Germany, ²Joint Academic Rheumatology Program, School of Medicine, National and Kapodistrian University of Athens. Centre of New Biotechnologies and Precision Medicine (CNBPM), School of Medicine, National and Kapodistrian University of Athens, Athens, Greece, Athens, Greece, ³PRIVATE PRACTICE, Patra, Greece, ⁴Rheumatology Department, University Hospitals Coventry and Warwickshire NHS Trust, Coventry, Coventry, United Kingdom, ⁵CHR ORLEANS, ORLEANS, France, ⁶Rheumatologische Schwerpunktpraxis, Berlin, Germany, ⁷Clinic of Rheumatology, University Hospital St. Ivan Rilski, Sofia, Bulgaria, ⁸GKM Gesellschaft für Therapieforschung mbH, Lessingstrasse, Munchen, Germany, ⁹Novartis Pharmaceuticals Corporation, East Hanover, NJ, ¹⁰Novartis Pharma AG, Basel, Switzerland, Basel, Switzerland, ¹¹Health Care - NHS, Norwich, United Kingdom
Background/Purpose: Real-world data on long-term use of secukinumab complements clinical trial findings by providing insights from diverse patients in routine clinical settings. SERENA (CAIN457A3403) was…
Abstract Number: 2553 • ACR Convergence 2024
Predictors of Biologic and Targeted Synthetic DMARD Initiation for Rheumatoid Arthritis Across Underserved Patient Groups: Insights from a National Cohort Study
Mark Russell¹, Mark Gibson², Benjamin Zuckerman¹, Kanta Kumar³, Shirish Dubey⁴, Maryam Adas², Edward Alveyn², Samir Patel¹, Zijing Yang¹, Katie Bechman², Elizabeth Price⁵, Sarah Gallagher⁶, Andrew Cope², Sam Norton¹ and James Galloway⁷, ¹King's College London, London, England, United Kingdom, ²King's College London, London, United Kingdom, ³University of Birmingham, Birmingham, United Kingdom, ⁴Oxford University Hospitals NHS FT, Oxford, United Kingdom, ⁵Great Western Hospital NHS Foundation Trust, Swindon, England, United Kingdom, ⁶British Society for Rheumatology, London, United Kingdom, ⁷Centre for Rheumatic Diseases, King's College London, London, United Kingdom
Background/Purpose: Quantifying healthcare inequality is essential to addressing the imbalance in outcomes attributable to age, gender, ethnicity and multimorbidity. In this study, we analysed differences…
Abstract Number: 0141 • ACR Convergence 2024
The Effect of Systemic Immunosuppressive Therapies on Cardiovascular Risk in Psoriatic Arthritis Patients
Melody Esmaeili¹, Linh Truong², Nicole Ridolfi³, Eugenia Chen⁴ and Maida wong⁵, ¹University of California, Irvine, Orange, CA, ²University of California, Los Angeles, Los Angeles, CA, ³University of California, Irvine, Newport Beach, CA, ⁴Long Beach VA Hospital, Irvine, CA, ⁵Long Beach VA Hospital, Los Angeles, CA
Background/Purpose: Evidence demonstrates an increased prevalence of atherosclerotic cardiovascular disease (ASCVD) among psoriatic arthritis (PsA) patients. However, the relationship between immunosuppressive therapies and the development of ASCVD remains unclear.…
Abstract Number: 0412 • ACR Convergence 2024
Impact of Approval of Biologic DMARDs on JIA Outcomes in a Single Center
Anna Sutton¹, Erin Balay-Dustrude¹, Beth A Mueller¹ and Susan Shenoi², ¹University of Washington, Seattle, WA, ²Seattle Children's Hospital and Research Center, Mercer Island, WA, WA
Background/Purpose: In clinical trials, biologic disease-modifying antirheumatic drugs (bDMARDs) for juvenile idiopathic arthritis (JIA) have demonstrated good efficacy. However, less is known about the impact…
Abstract Number: 0527 • ACR Convergence 2024
Risk Factors for Leukopenia in Asian Patients with Rheumatoid Arthritis Undergoing Tocilizumab
Ping Hsuan Kuo¹, Pu-Jun Fang² and Ming‑Han Chen³, ¹Taipei Veterans General Hospital, Taipei City, Taiwan (Republic of China), ²Tri-service general hospital, Taipei, Taiwan (Republic of China), ³Division of Allergy, Immunology & Rheumatology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan, Taipei, Taiwan
Background/Purpose: Leukopenia is an established adverse effect associated with tocilizumab(TCZ) therapy. Nevertheless, the extent of risk and its correlation with infection rates among Asian rheumatoid…
Abstract Number: 0664 • ACR Convergence 2024
Impact of Hydroxychloroquine and Belimumab on Early Glucocorticoid Reduction in New-Onset Systemic Lupus Erythematosus: A Retrospective Analysis of Risk and Protective Factors
Takehiro Nakai¹, Sho Fukui², Yukihiko Ikeda³, Hiromichi Tamaki⁴, Mitsumasa Kishimoto⁵ and Masato Okada⁴, ¹St. Luke's International Hospital, Tokyo, Tokyo, Japan, ²Brigham and Women's Hospital, Brookline, MA, ³St Luke's international hospital in Japan, Tokyo, Japan, ⁴St. Luke's International Hospital, Tokyo, Japan, ⁵Department of Nephrology and Rheumatology, Kyorin University School of Medicine, Tokyo, Japan
Background/Purpose: Glucocorticoid is a critical treatment option for systemic lupus erythematosus (SLE). However, long-term use is associated with numerous side effects and an increased risk…
Abstract Number: 0944 • ACR Convergence 2024
Targeting Defective Macrophages to Restore Resolution of Inflammation in Rheumatoid Arthritis -Perspectives for an Autologous Secretome Therapy
Melanie Couturier¹, Francis Bonnefoy², emilie Gaiffe³, Charline Vauchy⁴, Suzanne Behlke², ERIC TOUSSIROT⁵ and Sylvain Perruche², ¹1MED’INN’Pharma, F-25000 Besançon, France, Besançon, France, ²MED’INN’Pharma, F-25000 Besançon, France, Besançon, France, ³INSERM CIC -1431 CHU Besançon, France, Besançon, France, ⁴INSERM CIC-1431, CHU de Besançon, Besancon, France, Besançon, France, ⁵university hospital of BESANCON, besancon, France
Background/Purpose: Impaired macrophage efferocytosis, a key hallmark of failed inflammation resolution, is reported in many immune-mediated inflammatory diseases, including in Rheumatoid Arthritis (RA). Hence the…
Abstract Number: 1265 • ACR Convergence 2024
Approach to Janus Kinase Inhibition for Juvenile Dermatomyositis Among Childhood Arthritis and Rheumatology Research Alliance (CARRA) and Paediatric Rheumatology European Society (PReS) Providers
Emily Datyner¹, Rebecca Nicolai², Silvia Rosina³, Angela Hamilton⁴, Kaveh Ardalan⁵, Brigitte Bader-Meunier⁶, Amanda Brown⁷, Raquel Campanilho-Marques⁸, Marc Jansen⁹, Susan Kim¹⁰, Bianca Lang¹¹, Liza McCann¹², Helga Sanner¹³, Meredyth Wilkinson¹⁴, Belina Yi¹⁵, Hanna Kim¹⁶, Matthew Sherman¹⁷, Stacey Tarvin⁴ and Charalampia Papadopoulou¹⁸, and the CARRA and PReS investigators, ¹Monroe Carell Jr. Children's Hospital at Vanderbilt, Nashville, TN, ²Division of Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy, ³IRCCS Istituto Giannina Gaslini, Genoa, Italy, ⁴Indiana University School of Medicine, Indianapolis, IN, ⁵Duke University School of Medicine, Durham, NC, ⁶Necker Hospital, Assistance Publique Hopitaux de Paris, Paris, France, ⁷University of Arkansas for Medical Sciences, Little Rock, AR, ⁸Lisbon Academic Medical Centre, Lisboa, Portugal, ⁹University Medical Center Utrecht, Utrecht, Netherlands, ¹⁰University of California, San Francisco, CA, ¹¹Dalhousie University and IWK Health, Halifax, NS, Canada, ¹²Alder Hey Children's NHS Foundation Trust, Liverpool, England, United Kingdom, ¹³Oslo University Hospital, Oslo, Norway, ¹⁴Great Ormond Street Institute of Child Health, London, United Kingdom, ¹⁵Johns Hopkins University School of Medicine, Baltimore, MD, ¹⁶National Institute of Arthritis Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ¹⁷DAIT/NIAID/NIH, Washington, DC, ¹⁸Great Ormond Street Hospital for Children, NHS Foundation Trust, London, United Kingdom
Background/Purpose: Janus kinase inhibitors (JAKi) have been proposed as a treatment for idiopathic inflammatory myopathies to target increased interferon signaling. Predominantly retrospective reports have demonstrated…
Abstract Number: 1469 • ACR Convergence 2024
Manhattan Study: Observational, Ambispective Study to Describe Persistence and Effectiveness of a Second-line Guselkumab or TNF Inhibitors After First-line TNF Inhibitors for the Treatment of Active Psoriatic Arthritis in Spain
María Rocío González Molina¹, C Marín Huertas², B Joven-Ibáñez³, L de Prado⁴, Lourdes Mateo⁵, M Llanes Gómez⁶, A Hernández del Río⁷, EA Blanco-Morales⁸, J Malavé Calzada⁹, Meritxell Sallés Lizarzaburu¹⁰, Inmaculada Ros-Vilamajó¹¹, Martina Steiner¹², EVELIN CERVANTES PEREZ¹³, Vanesa Hernández-Hernández¹⁴, S Castro Oreiro¹⁵, ANA URRUTICOECHEA¹⁶, L Orpinell Palacio¹⁷, J Campos Esteban¹⁸, Raúl Veroz González¹⁹, O Camacho Alcázar²⁰, MP Moreno-Gil²¹, A Aragón Díez²², MJ Moreno-Ramos²³, FJ Maceiras Pan²⁴, S Díaz-Castroverde²⁵, Santiago Muñoz Fernández²⁶, JA Pinto Tasende²⁷ and J Ramírez García²⁸, ¹Hospital Reina Sofía, Murcia, Murcia, Spain, ²Hospital Infanta Leonor, Madrid, Madrid, Spain, ³Hospital Universitario 12 de Octubre, Madrid, Madrid, Spain, ⁴Hospital de Mollet, Mollet del Vallès, Barcelona, Catalonia, Spain, ⁵H Germans Trias i Pujol, Barcelona, Spain, ⁶Hospital Juan Ramón Jiménez, Huelva, Andalucia, Spain, ⁷Hospital Naval, Ferrol, A Coruña, Galicia, Spain, ⁸Hospital Virgen del Rocío, Sevilla, Andalucia, Spain, ⁹Hospital Virgen del Puerto, Plasencia, Cáceres, Extremadura, Spain, ¹⁰Althaia Xarxa Assistencial Universitària Manresa, Manresa, Catalonia, Spain, ¹¹Hospital Universitari Son Llàtzer, Palma de Mallorca, Islas Baleares, Spain, ¹²Department of Rheumatology. Hospital Universitario Infanta Sofía., Madrid, Spain, ¹³Complejo Hospitalario Universitario de Pontevedra, Pontevedra, Galicia, Spain, ¹⁴Hospital Universitario de Canarias, San Cristobal de La Laguna, Canarias, Spain, ¹⁵Hospital Sant Joan XXIII, Tarragona, Catalonia, Spain, ¹⁶Hospital Universitario Son Espases, Palma de Mallorca, Islas Baleares, Spain, ¹⁷Hospital Sagrat Cor, Barcelona, Spain, ¹⁸Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain, ¹⁹Hospital Mérida, Badajoz, Spain, ²⁰Hospital Sant Joan Despí Moisès Broggi, Sant Joan Despí, Barcelona, Catalonia, Spain, ²¹Hospital San Pedro de Alcántara, Cáceres, Extremadura, Spain, ²²Hospital Universitario de Getafe, Getafe, Madrid, Madrid, Spain, ²³Hospital Virgen de Arrixaca, Murcia, Murcia, Spain, ²⁴Hospital de Meixoeiro, Pontevedra, Galicia, Spain, ²⁵Johnson&Johnson Innovative Medicine, Madrid, Madrid, Spain, ²⁶Hospital Universitario Infanta Sofía. Universidad Europea de Madrid, Madrid, Spain, ²⁷Complejo Hospitalario Universitario, A Coruña, Spain, ²⁸Hospital Clínic, Barcelona, Spain
Background/Purpose: PsA is a complex inflammatory condition affecting both the skin and musculoskeletal system. Clinical guidelines recommend biological therapies after conventional synthetic DMARDs (csDMARDs) inadequate…

« Previous Page
1
…
3
4
5
6
7
…
54
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].